Fidelity SPDR Advertisement
Home > Boards > US OTC > Medical - Drugs >

Advanced Cell Technology Inc. (ACTCD)

Add ACTCD Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator locksflooring, sports guy, Kapla, LODE MAKING ME RICH, homeslice10, lasers
Search This Board:
Last Post: 8/29/2014 4:18:33 AM - Followers: 634 - Board type: Free - Posts Today: 8

Advanced Cell Technology, Inc. (ACTC)




Company Headquarters:

Advanced Cell Technology, Inc.
P.O. Box 1700
Santa Monica, CA 90406

Tel: (310) 576 0611
Fax: (310) 576 0662


Massachusetts Laboratory Facility
33 Locke Dr.
Marlborough, MA 01752
Tel: (508) 756-1212
Fax: (508) 229-2333


Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC) is a biotechnology company developing cellular therapies for the treatment of diseases that impact millions of people worldwide. The company is currently conducting the only ongoing, FDA-cleared human embryonic stem cell (hESC)-based human clinical trials. The two trials, initiated in July 2011 at UCLA's Jules Stein Eye Institute, use retinal pigment epithelial (RPE) cells derived from hESCs to treat forms of macular degeneration. ACT also recently received approval from the UK Medicines & Healthcare Products Regulatory Agency (MHRA) to conduct the first hESC trial in Europe. The company is also developing its Hemangioblast (HG) platform for the treatment of blood and cardiovascular diseases, its Phase II-cleared Myoblast stem cell therapy for the treatment of chronic heart failure and other cardiac conditions, and other programs.

ACT's principal laboratory and GMP facility is in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California. ACT is led by an experienced management team and a world-class scientific team helmed, respectively, by interim chairman and CEO Gary Rabin and chief scientific officer Robert Lanza, M.D.


ACT owns or licenses more than 150 patents and patent applications related to stem cell therapy and regenerative medicine, and is positioning itself to have a dominant patent position around its stem cell-derived RPE program in leading markets around the world.
In 2010 ACT secured three far-reaching patents related to its RPE program, and more recently was issued the first patent for generating hemangioblast cells to treat a broad spectrum of vascular and hematopoietic disorders.

The company's RPE and HG programs are hESC-based, and its Myoblast program for cardiac disease is an adult autologous stem cell therapy. As documented in NATURE and Cell Stem Cell, ACT developed the "single-cell blastomere" technique, the first-ever proven alternative method for successful hESC generation without harm to the embryo, for which it was recently issued a broad patent
RPE Program - ACT has developed a fully-differentiated RPE cell derived from human embryonic stem cells, which can be used as a cellular therapy to treat retinal degenerative diseases. In July 2011 ACT initiated two Phase I/II clinical trials to test the safety of the therapy for Stargardt's Macular Dystrophy (SMD), and for Dry Age-Related Macular Degeneration (Dry AMD). Dry AMD represents a $25-30 Billion market in the US and Europe alone, and there are no approved therapies currently available for either condition. Two patients have thus far been treated at UCLA, Institutional Review Board (IRB) approval for the SMD clinical trial has also been issued by Oregon Health & Science University (OHSU) and European regulatory clearance has been granted to initiate the first hESC trial in Europe.
Other recent milestones in ACT's RPE program include: the NIH proposed expanding its definition of hESCs for funding purposes, in part to accommodate ACT's lines derived using its patented "embryo-safe" single-cell blastomere technique; and both the FDA and the European Medicines Agency (EMA) granting ACT's RPE cells "Orphan" status for treatment of Stargardt's Disease.
Hemangioblast Program - ACT's Hemangioblast program is for the treatment of blood and cardiovascular diseases. A paper published in NATURE Methods revealed the company's successful generation of functional Hemangioblast cells from human embryonic stem cells, and a paper published earlier this year in Cell Research indicated that hESCs could be a potentially unlimited source of platelets for transfusion.
Myoblast Program - ACT's Myoblast treatment may prove particularly beneficial for patients who have experienced a serious heart attack and are at risk for heart failure. ACT has secured FDA approval to commence with Phase II clinical trials. The Myoblast program has several advantages over currently-available approaches, including symptom management and disease modification.

Dr. Lanza explains some of the technology we are pursuing:

For more information visit



Share Structure as of November 30, 2011:

Outstanding Shares

Reserved Shares

Authorized and Unreserved Shares



Authorized Preferred Shares



The following table sets forth information regarding beneficial ownership of our capital stock as of November 30, 2011 by:

·  5% or greater stockholders;
·  Each of our directors and named executive officers; and
·  All of our directors and executive officers, as a group.


Name and Address (1) of Beneficial Owner                                                                                         Common Stock Beneficially Owned                   Percentage of Shares Beneficially Owned 
5% or Greater Stockholders
Directors and Named Executive Officers
William M. Caldwell, IV**                                                                                                                             95,415,141 (1)                                                           5.58%%

Robert P. Lanza, M.D.                                                                                                                                  51,199,082 (2)                                                           2.97%%

Alan C. Shapiro                                                                                                                                           20,150,927 (3)                                                           1.18%%
Erkki Ruoslahti                                                                                                                                            2,500,000 (4)                                                                *
Gary Rabin                                                                                                                                                 23,087,430 (5)                                                           1.35%
Directors and Executive Officers as a Group (5 Persons)                                                                                192,352,580                                                               11.08%%


* Less than 1%

** Mr. Caldwell passed away on December 13, 2010

(1) Includes 5,108,546 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(2) Includes 17,583,207 shares subject to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

(3) Includes (i) 17,032,587 shares subject to convertible debentures, board fees, common stock grant held by The Shapiro Family Trust and of
which Dr. Shapiro may be deemed the beneficial owner, (ii) 3,018,340 shares subject to warrants in connection with the 2005-2008
convertible debentures, and (iii) 100,000 shares subject to stock options that are currently exercisable or exercisable within 60 days of
November 30, 2011.

(4) Includes 100,000 shares issuable upon exercise of options exercisable within 60 days of November 30, 2011. Effective August 1, 2011,
Erkki Ruoslahti resigned from the Board of Directors of the Company.

(5) Includes indirect ownership of (i) 1,239,501 shares issued to PDPI, LLC on December 22, 2010, upon exercise of certain warrants, which
such number of shares represents Mr. Rabin's proportional interest in the total number of shares held by PDPI, LLC, based on his 33.33%
equity interest in the entity. Mr. Rabin disclaims beneficial ownership in the shares held by PDPI, LLC, and (ii) 7,000,000 shares subject
to stock options that are currently exercisable or exercisable within 60 days of November 30, 2011.

There are no arrangements known to the Company, including any pledge by any person of securities of the Company, the operation of
which may at a subsequent date result in a change in control of the Company.

Media Relations

Bill Douglass
Gotham Communications, LLC
bill [at] gothamcomm [dot] com


Martina Schwarzkopf, Ph.D.
Russo Partners, LLC
(212) 845-4292
martina.schwarzkopf [at] russopartnersllc [dot] com

Investor Relations

James Young
jyoung [at] ceocast [dot] com
(212) 732-4300






All messages, including iBox content, are the opinion of the posters, are no substitute for your own research, and should not be relied upon for stock trading or any other purpose.




Rules of the board according to IHUB:


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
Current Price
Bid Ask Day's Range
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: OTC Stocks Daily Trading Focus: Windstream Technologies, Inc. Blue Earth, Inc. Creative Edge Nutrition, Inc. Brainstorm Cell ... 07/01/2014 08:00:00 AM
ACTC News: Current Report Filing (8-k) 05/29/2014 05:00:40 PM
ACTC News: Quarterly Report (10-q) 05/08/2014 04:41:06 PM
ACTC News: Amended Annual Report (10-k/a) 04/29/2014 04:36:14 PM
#67180  Sticky Note $ACTC's May2014 Presentation Posted since on $ACTC website. Enjoy! lasers 06/06/14 12:22:51 AM
#71309   You're right, phase 1 or lack there of Auger08 08/29/14 04:18:33 AM
#71308   Very good post! Ive been with this asuato 08/29/14 04:18:04 AM
#71307   ACTC, an ill-liquid NIGHTMARE! For the shorts, heh!!! rumper 08/29/14 02:29:20 AM
#71306   Low Volume, LOL ACTC could gap higher! rumper 08/29/14 02:19:10 AM
#71305   If this were a Miss America contest ACTCD ddls 08/29/14 12:42:55 AM
#71304   Seriously, everyone has a right to an opinion elysse1kittycat 08/29/14 12:32:23 AM
#71303   You very smart, very intuitive investor Mr.Doglover1, and ddls 08/29/14 12:24:53 AM
#71302   To achieve NASDAQ listing $ACTCD, IMO, may perhaps lasers 08/29/14 12:14:18 AM
#71301   Also my thoughts are that they would want art2426 08/28/14 11:38:27 PM
#71300   Lol... Way better chance to go to 30. Auger08 08/28/14 11:13:41 PM
#71299   $2-$3 in 30 days had as much chance elysse1kittycat 08/28/14 10:56:49 PM
#71298   Yes we all know that. However we are lasers 08/28/14 08:13:54 PM
#71297   ACT is looking for partnerships, not a buyout. elllk 08/28/14 08:04:03 PM
#71296   Mkt Cap $ACTCD at $7.84 and 34 mil lasers 08/28/14 07:59:49 PM
#71295   That's more than twenty times the current market Cisco_Tajuara 08/28/14 07:49:29 PM
#71294   On the other hand if a Major Pharma lasers 08/28/14 07:40:50 PM
#71293   Let's hope the plan from the sidelines doesn't homeslice10 08/28/14 06:52:16 PM
#71292   I am right there with you on the Auger08 08/28/14 06:24:39 PM
#71291   Thanks for your post CAT. farviewhill 08/28/14 04:18:25 PM
#71290   Yes, that was what I thought too: Goodbuddy4863 08/28/14 04:17:10 PM
#71289   Thanks Lasers, your post are informative. chuckanutman 08/28/14 04:06:03 PM
#71288   Super $7.84 EOD closing. MMs and their flippers lasers 08/28/14 04:03:44 PM
#71287   We will see later. However MMs need to lasers 08/28/14 03:56:55 PM
#71286   I've been holding ACTC and watching this board cat815 08/28/14 03:55:59 PM
#71285   Again, this has been planned for some time, JPValas 08/28/14 03:55:52 PM
#71284   Perhaps Tufts news ahead. chuckanutman 08/28/14 03:53:11 PM
#71283   The REAL reason for reverse stock splits is doglover1 08/28/14 03:49:46 PM
#71282   I was following pre-market activity this morning and MYMEBAHT 08/28/14 03:39:26 PM
#71281   Absolutely a problem to determine the assets value lasers 08/28/14 03:27:15 PM
#71280   They must b propping us up homeslice10 08/28/14 03:21:57 PM
#71279   Are you forgetting extant Lincoln Park? north40000 08/28/14 03:20:19 PM
#71278   Equity value of patents and applications for patent north40000 08/28/14 03:15:28 PM
#71277   Just think that once we uplist, this will Auger08 08/28/14 02:55:28 PM
#71275   People get too hung up on the PPS... interstate 08/28/14 02:45:59 PM
#71274   IMO that is why $ACTCD did the R/S lasers 08/28/14 02:45:21 PM
#71273   Ah interesting, thanks for the link. Can't wait Auger08 08/28/14 02:43:09 PM
#71272   regsho finra filing with SEC. lasers 08/28/14 02:42:21 PM
#71271   Where are you getting that 20m naked short Auger08 08/28/14 02:38:35 PM
#71269   We will see later. However MMs need lasers 08/28/14 02:36:58 PM
#71268   Lots of shares changed hands today. Lots of Auger08 08/28/14 02:29:59 PM
#71267   The ACTC/Team is a "Cohesive Unit" :) chuckanutman 08/28/14 02:27:36 PM
#71266   Thanks, Aussie. farviewhill 08/28/14 02:21:33 PM
#71265   ACTC Ice Bucket Challenge video: (I hope link works) abbey1212 08/28/14 02:18:17 PM
#71264   might be the wisest choice to release any fulleroots 08/28/14 02:12:43 PM
#71263   ACTC/Team having fun !!! chuckanutman 08/28/14 02:06:30 PM
#71262   Haha regenerative ice! andyshow 08/28/14 02:04:00 PM
#71260   Don't know why you're posting if you don't JPValas 08/28/14 02:02:24 PM
#71258   Great post art2426 "One more checked chuckanutman 08/28/14 01:55:56 PM
#71257   NOT INSIDE INFORMATION. If the information is cty 08/28/14 01:52:46 PM
#71256   Lebowsky total nonsense for you also! lasers 08/28/14 01:42:10 PM